Non Small Cell Lung Cancer Market

Non-Small Cell Lung Cancer Therapeutics Market (Pipeline - Early Stage (Phase I and II) and Late Stage (Phase III); Drug Class - Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

  • Rep Id : TMRGL504
  • Published On : Nov 2015
  • No. of Pages : 94
  • Category : Pharmaceutical


1. Preface
    1.1. Report Description
    1.2. Research Methodology
    1.3. Market Segmentation

2. Executive Summary
    2.1. Market Snapshot
    2.2. Comparative Analysis: Non-Small Cell Lung Cancer Market, by Geography, 2014 & 2023 (Value %)

3. Non-Small Cell Lung Cancer Market Overview
    3.1. Introduction
    3.2. Treatment Guidelines and Disease Management
    3.3. Companion Diagnostics: Overview
    3.4. Regulatory Scenario
    3.5. Market Dynamics
          3.5.1. Drivers
          3.5.2. Restraints
          3.5.3. Opportunities
    3.6. Event Impact Analysis, 2013 - 2023
    3.7. Market Attractiveness Analysis of Global Non-Small Cell Lung Cancer Market, by Geography, 2014
    3.8. Competitive Landscape
3.8.1. Market Share Analysis of Key Players, 2014 (Value %)

4. Market Segmentation – By Drug
    4.1. Overview  
    4.2. Global Non-Small Cell Lung Cancer Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
          4.2.1. Global Angiogenesis Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.2. Global EGFR Blockers Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.3. Global Kinase Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.4. Global Microtubule Stabilizer Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.5. Global Folate Antimetabolites Market Revenue, 2013–2023 (US$ Mn) and Analysis
          4.2.6. Global PD-1/PD-L1 Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis

5. Pipeline Analysis
    5.1. Overview 
    5.2. Late Stage (Phase III) 
          5.2.1. Avelumab - Pfizer, Inc.
          5.2.2. MPDL3280A - Roche
          5.2.3. MEDI4736  - AstraZeneca
          5.2.4. Abemaciclib – Eli Lilly and Company 
          5.2.5. Others
    5.3. Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)

6. Market Segmentation – By Geography
    6.1. Introduction
    6.2. Global Non-Small Cell Lung Cancer Market Revenue, by Region, 2013–2023 (US$ Mn)    
    6.3. North America Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
          6.3.1. U.S. Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.3.2. Canada Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
    6.4. Europe Non-Small Cell Lung Cancer Market – Revenue, by Country, 2013–2023 (US$ Mn)
          6.4.1. U.K. Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.4.2. Germany Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.4.3. Rest of Europe Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
    6.5. Asia Pacific Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
          6.5.1. Japan Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.5.2. China Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
          6.5.3. Rest of APAC Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
    6.6. Rest of the World Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)

7. Recommendations
    7.1. Recommendation 1: Research and Development Initiatives to Penetrate the Market
    7.2. Recommendation 2: Investment in Emerging Economy 

8. Company Profiles
    8.1. Astra Zeneca PLC
    8.2. Boehringer Ingelheim
    8.3. Bristol-Myers Squibb
    8.4. Celgene Corporation
    8.5. GlaxoSmithKline PLC
    8.6. Eli Lilly & Co.
    8.7. Pfizer, Inc.
    8.8. Genentech, Inc. (a Roche company)
    8.9. Sun Pharmaceutical Industries Ltd.

.